Mazdutide
Mazdutide (LY3305677 / IBI362)
China's dual-agonist obesity drug in late-stage trials
Mazdutide is a dual GLP-1 and glucagon receptor agonist developed by Eli Lilly and licensed to Innovent Biologics in China. Phase 3 trials show approximately 15-18% weight loss.
Admin routes
Subcutaneous
Popularity
Niche
Side effects
Generally mild
AU vendors
0 rated
✓Key benefits
📈What to expect
Early weight loss during dose escalation period
Approximately 10-12% body weight reduction
Approximately 17% body weight reduction at full dose
Based on community reports and published research. Individual results vary significantly.
💊Dosing protocols
Obesity (Phase 3 trial dose)
Up to 9 mg
Once weekly (subcutaneous)
Ongoing treatment with dose escalation
Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.
Research status|Phase 3 trials in China, NDA submission planned
Overview
Mazdutide is a once-weekly injectable dual GLP-1/glucagon receptor agonist. It works through similar principles as survodutide and retatrutide but was developed through the Lilly-Innovent partnership for the Chinese market. In the GLORY-2 Phase 3 trial, mazdutide 9 mg produced approximately 17.4% weight loss at 48 weeks in Chinese adults with obesity. The glucagon receptor component may help preserve metabolic rate and target liver fat more effectively than pure GLP-1 agonists. Innovent is pursuing approval in China, while Lilly retains rights for other markets.
⚙️How it works
Mazdutide activates both GLP-1 receptors and glucagon receptors. GLP-1 receptor activation slows gastric emptying, increases satiety, and improves insulin secretion. Glucagon receptor activation increases energy expenditure, promotes hepatic fat oxidation, and may help prevent the metabolic rate decline typically seen with weight loss. The dual action aims to produce greater weight loss than GLP-1 alone while better preserving lean mass and metabolic rate.
⚡Side effects
📅Research history
Innovent Biologics licenses mazdutide from Eli Lilly for China
GLORY-2 Phase 3 results published showing 17.4% weight loss
References
- [1]Ji L, et al. 'Efficacy and safety of mazdutide in Chinese adults with obesity: GLORY-2 Phase 3 trial.' Lancet Diabetes & Endocrinology, 2024.
Frequently asked questions
Related peptides
Semaglutide
Weight ManagementThe GLP-1 agonist behind the weight loss revolution
5 rated vendors
Tirzepatide
Weight ManagementThe dual-action GLP-1 that outperforms Ozempic in every trial
2 rated vendors
Retatrutide
Weight ManagementThe triple agonist showing 24% weight loss in trials
1 rated vendors
Liraglutide
Weight ManagementThe original daily GLP-1 agonist for weight and metabolic health
0 rated vendors
Cagrilintide
Weight ManagementLong-acting amylin analog powering CagriSema
0 rated vendors
Community experiences
Share your experience with Mazdutide. Effects, side effects, protocol details - help others make informed decisions.
No community reviews yet. Be the first to share your experience with Mazdutide.
Need to calculate your dose?
Use our free reconstitution calculator to work out syringe units for Mazdutide.
Open CalculatorFound this useful?
Share this guide
Disclaimer: This guide is for educational and informational purposes only. It is not medical advice. The dosing protocols listed are sourced from published research and community reports and do not constitute a recommendation. Always consult a qualified healthcare professional before using any peptide. Australian regulations classify many peptides as Schedule 4 (prescription-only) substances. Check current TGA guidelines before purchasing.